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When herpes simplex virus was inoculated into the flank of a BALB/c mouse by scarification, the local
replication of virus was followed by the establishment of an acute ganglionic infection. The subsequent
centrifugal spread of this virus along nerves to the skin of the whole dermatome led to the development of a
bandlike "zosteriform" rash. This represents a highly reproducible system in which virus travels through the
nervous system synchronously in large numbers of animals. The transection of peripheral nerves at various
times after infection showed that the virus had completed the round trip 60 h after inoculation into the upper
flank and was detectable as infectious virus by 74 h postinfection. After the administration of virus, neutralizing
but not nonneutralizing antibodies prevented the development of the zosteriform rash. The target epitopes of
the protective antibodies were not confined to a single glycoprotein. Neutralizing antibody was effective even
when given up to 60 h postinfection and was protective even when administered after sensory neurotomy at this
time. Antibody was therefore able to prevent clinically and virologically detectable infection of the skin,
presumably by acting peripherally on virus emerging from nerve endings. A quantitative estimate of the action
of one of the neutralizing monoclonal antibody preparations, AP7, showed that high titers (several times higher
than those normally found in immune mice) were needed to prevent this type of infection. These results are
discussed in relation to antibody prophylaxis.
The role of immunity in modifying the course of both
primary and recurrent herpes simplex virus infection has
received considerable attention in recent years (15). The
paradoxical occurrence of recrudescent lesions in humans in
the face of immunity, often with no detectable rise in
circulating neutralizing antibodies (5), leads one to address
the question of whether specific immune processes can play
any significant role in the prevention of recurrent disease.
We have recently described a model for investigating the
mechanisms of immunity in experimental herpes (23). The
infection of mice in the flank led to the development of
ganglionic infection, and the subsequent delivery of virus to
the skin of the whole dermatome, by nerve fibers. Mice
infected in this way develop a band-like "zosteriform" rash
several days after the initial inoculation of virus, a phenom-
enon first noticed by Teague and Goodpasture in 1923 (25).
The significance of this model is that the epidermal cells
distant from the inoculation site become infected from nerve
endings, a process which also occurs during the develop-
ment of a recrudescent lesion. Although in our model system
no reactivation has preceded the delivery of virus to the
skin, the peripheral events can be used to study the action of
immunological effector mechanisms on the prevention or
modulation of infection in the epidermis after centrifugal
spread of virus from the ganglion.
We report here the results of further studies in this
system, investigating the effect of antibodies on the devel-
opment and course of zosteriform lesions. The possibility
that antibodies may indeed be able to prevent recrudescence
is discussed in the context of existing knowledge.
MATERIALS AND METHODS
Mice. Female inbred BALB/c mice, raised in the depart-
ment animal house, were used throughout. They were in-
fected at 6 to 8 weeks of age.
* Corresponding author.
Virus. A well-characterized clone of a recent oral isolate
of herpes simplex virus type 1, strain SC16 (7), was grown in
BHK-21 cells and stored in samples at -70°C until required.
Inoculation of mice. The left flank was clipped and depil-
ated with Nair (Carter-Wallace Ltd., Folkestone, United
Kingdom). The mice were then lightly anesthetized with
ether and inoculated with 5 x 104 PFU of virus, as previ-
ously described (23).
Removal of tissue and infectious virus assay. Tissue sam-
ples from the inoculation site and lower flank were taken
separately as previously described (23). To assay for the
presence of infectious virus, tissue was homogenized in 1 ml
of Glasgow modified Eagle medium containing 10% calf
serum and 10% tryptose phosphate. Ten-fold dilutions were
then tested for plaque production with BHK-21 cells (19).
Antibodies. The monoclonal antibodies AP7, LP2, and
LP11, LP3 were kindly donated by A. Buckmaster and A.
Minson of this department. Antibody 20cxD4 was a generous
gift from W. Rawls (Department of Pathology, McMaster
University, Ontario, Canada). The relevant properties of
these antibodies are summarized alongside the experimental
results. Polyclonal hyperimmune serum (neutralization titer
of 1:150 in the presence of complement) was produced in
BALB/c mice by repeated monthly subcutaneous injections
of SC16.
Antibody assays. Neutralization was measured by 50%
plaque reduction in BHK-21 cells as previously described
(10). Nonneutralizing antibodies were quantified in an en-
zyme-linked immunosorbent assay with a monolayer of
infected BHK-21 cells fixed to plastic multiwell plates. Serial
dilutions of test antibody were reacted with the monolayer
for 45 min at room temperature. Binding was determined
by sheep anti-mouse immunoglobulin G linked to 3-galac-
tosidase developed with a substrate consisting of o-
nitrophenyl-3-D-galactopyranoside in i0-3 M magnesium
sulfate. After the addition of 1 M sodium carbonate, color
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TABLE 1. Prevention of zosteriform spread by the administration
of antibody on day 1 postinfection
Immuno- Zosteri-
Antibody Neutralization globulin Target gly- form pro-in vitro G sub- coprotein
class tection
LP2 + 2a gDa +
AP7 + b 2a gDa +
LP11 + 2a 110Ka'c +
Immune serum + NA" NAd +
LP3 - 2a gDaa
20aD4 - 1 gA/Be
a Data from A. Minson (personal communication).
b Complement dependent.
Not yet named.
d NA, Not applicable.
eData from reference 1.
intensity was read at 410 nm. The antibodies gave a binding
titer of 1:100 or greater in this test.
Neurotomy. Sensory denervation of the left flank was
performed through a posterior midline incision as previously
described (23). The animals were anesthetized with intraperi-
toneal diazepam and fentanyl. Control animals received a
similar operation without division of the nerves.
RESULTS
The effect of neutralizing monoclonal antibody AP7 on the
recovery of virus from the skin. The relevant properties of
AP7 are summarized in Table 1. A sample of 100 RIl of this
antibody was administered intravenously to five groups of
three mice on day 1 postinfection, resulting in serum neu-
tralizing titers in excess of 1:200 in each animal. Groups
were killed daily, and the skin of the inoculation site and
lower flank of each mouse was separately tested for the
presence of infectious virus. The titers were compared with
controls that received saline instead of AP7 (Fig. 1). The
administration of AP7 on day 1 had no significant effect on
the amount of virus recovered from the inoculation site on
days 2 and 3 postinfection. However, although high titers of
virus were isolated from the lower flank of controls on days
4 and 5, no virus was found at this site in antibody-treated
groups. This corresponded with a failure of the antibody-
treated mice to develop zosteriform rashes.
Comparison of various monoclonal antibodies. Five mono-
clonal antibodies, each with different properties, and poly-
clonal hyperimmune serum were screened for the ability to
prevent zosteriform spread when administered on day 1
postinfection. The results are indicated in Table 1, along
with the properties of each antibody. The only property that
correlated with the ability of an antibody to prevent virus
spread was the ability to neutralize virus in vitro. Quantita-
tion of the protective effect of one of the neutralizing
monoclonal antibodies, AP7, is discussed below.
Time at which infectious virus can be detected in the lower
flank. Virus can be consistently found remote from the
inoculation site on day 3 postinfection (23). We have ana-
lyzed the timing of this event more precisely (Fig. 2). Groups
of 10 mice were screened at 2-h intervals, from 68 to 76 h
postinfection, for the presence of infectious virus in the
lower flank. Virus was not found in any mice at 68 h
postinfection but by 74 h, all of the mice in the group were
positive.
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FIG. 1. The effect of antibody given 24 h postinfection on the
recovery of virus from the inoculation site and lower flank. Shown
are virus isolated from the inoculation site (40) and lower flank (U) of
control mice and from the inoculation site (A) and lower flank (O) of
mice receiving AP7 on day 1 postinfection. Each point represents
the geometric mean titer obtained from a group of three animals.
Vertical bars indicate the range of values.
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FIG. 2. Time of appearance of virus in the lower flank. Groups of
10 mice were killed at 2-h intervals from 68 h postinfection onwards.
Samples of skin from the lower flank were screened for infectious
virus. By 74 h postinfection, virus was found in all mice in the
group.
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TABLE 2. Effect of neurotomy at various times on the
occurrence of zosteriform spread
No. of mice with lesions/no. tested on
Neurotomy day 5
(h postin- No AP7 AP7 afterfection) after op- operation
eration
54 0/10 0/0
60 9/10 1/0
66 10/10 9/10
Delay of antibody administration. The effect of delaying
the administration of antibody (AP7) was also investigated.
Groups of 10 mice received antibody at various times
postinfection and were examined for the appearance of
zosteriform rashes on day 5. AP7 was effective when admin-
istered at 54 and 60 h postinfection, after which (at 66 h
postinfection and when no antibody was used) its protective
effect was lost.
Precise time at which virus arrives in lower flank. It has
been previously shown that sensory neurotomy before in-
fection of the flank prevents zosteriform spread (23) because
virus is denied access to the nervous system. It was also
shown that, with the nerves intact, virus was demonstrable
in the sensory ganglia 48 h postinfection. By the division of
sensory nerves to the flank at various times after infection
(from 48 h onwards), we were able to estimate the time at
which virus makes the return trip to the periphery (Table 2).
Control mice underwent a similar operation, except that the
nerves were left intact. The results indicate that from 60 h
postinfection onwards, virus was peripherally located (i.e.,
in the flank) because at this time neurotomy no longer
prevented the development of the zosteriform rash, which
appeared between days 4 and 5, in synchrony with controls.
Antibody after nerve section. To demonstrate that an
entirely peripheral action of AP7 was sufficient to suppress
the formation of the zosteriform rash, additional groups of
mice from the previous experiment received AP7 immedi-
ately after sensory neurotomy (Table 2). These animals were
RECIPROCAL ANTIBODY TITRE (60 hrs p.i.)
250 200 150 100 50
also examined for the appearance of lesions on day 5,
compared with the group that received the operation but no
antibody. As previously indicated, at 60 h postinfection,
neurotomy alone did not prevent the development of rashes.
However, antibody was shown to be effective at this time;
AP7 thus remained highly effective at 60 h postinfection,
even though it was given after the nerves were cut.
Amount of AP7 required. The ability of AP7 to prevent the
formation of the zosteriform lesion when given before infec-
tion and at 24 and 48 h postinfection was quantified in terms
of the serum neutralization titer that had to be achieved (Fig.
3). At each time point, 100 ,ul of diluted ascitic fluid was
given to each mouse. Groups of five mice were studied, and
control mice received saline. Serum neutralization titers
were determined 60 h postinfection. The results clearly
indicate that high titers of AP7 were required to neutralize
the infection.
DISCUSSION
Zosteriform spread of herpes simplex virus, as indicated
by the appearance of infectious virus distant from the
inoculation site, occurred by 74 h postinfection. Therefore,
since the bandlike rash caused by the centrifugal spread of
virus includes the site of inoculation, it must be assumed that
virus recovered from this site after 74 h is not entirely the
result of local replication. This fact must be taken into
account when studying agents that accelerate the clearance
of virus from the skin. In such instances, an apparent
reduction in local virus growth may well result from an
inhibition of the zosteriform component without necessarily
acting directly on infected peripheral cells. This was found
to be the case with the neutralizing antibody AP7, in which
zosteriform spread was completely inhibited by intravenous
antibody given 24' h postinfection. However, at the inocula-
tion site, early replication (uncomplicated by zosteriform
spread) was not significantly different in antibody-treated
and control groups.
It has been shown that antibodies are generally unable to
affect cell-to-cell spread of herpes simplex virus in infected
tissue culture monolayers (9). Our results indicate that this
may also be the case in vivo, after an infection in the
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FIG. 3. Amount of AP7, given at various times postinfection, required to prevent zosteriform spread. Samples of 100 ,ul of neat or diluted
ascitic fluid were given to each mouse, producing the range of serum neutralization titers shown on the left-hand side of the figure. A rapid
drop in the protective effect was observed with dilution of the antibody preparation.
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epidermis has been initiated. The possibility of antibody-de-
pendent cellular cytotoxicity is recognized, but as yet there
is no evidence that AP7 participates in such a mechanism in
vivo. We are further investigating the role of this process in
the host defense against herpes simplex virus, using both
monoclonal and polyclonal antibody preparations.
The efficacy of antibody in preventing the zosteriform
lesion was maintained up to and including 60 h postinfection.
At this time, virus was already located peripherally, and we
therefore conclude that the presence of AP7 in skin alone
was sufficient to prevent the appearance of a zosteriform
rash. This conclusion is reinforced by the demonstration that
AP7 was effective even when given after sensory neuro-
tomy, thereby excluding a role for antibody operating in the
peripheral or central nervous systems at these times. In-
deed, McKendall (13) has shown that radioactively labeled
purified immunoglobulin G only appears in the central nerv-
ous system after breaching the blood-brain barrier some 5 to
6 days after infection. McKendall also showed that intrave-
nously administered immunoglobulin quickly infiltrates pe-
ripheral tissues in detectable amounts. However, in the
absence of inflammation (which is the case during the first 24
to 48 h of mouse flank infection [23]), the diffusion of
antibody molecules into tissue would be expected to be
rather poor, and this may be the reason why a large amount
of AP7 was required to produce the protective effect. The
titer needed was at least fivefold higher than the titer we
routinely find by the same assay in previously infected mice.
The protective effect was only seen with neutralizing
antibodies; no protection was observed with nonneutralizing
monoclonal antibody preparations. For this reason, one
assumes that virus is neutralized when it passes from nerve
ending to epidermal cell. Once virus becomes intracellular
(60 to 66 h postinfection), neutralizing antibodies have no
effect.
A substantial number of investigations have been made in
the past into the role of antibodies in protection against
herpes simplex virus infection. Nearly all have been based
on passive transfer experiments. Conflicting results obtained
in various experimental systems lead to continued confusion
over the role of antibodies at the various stages of natural
infection. In 1946, Evans et al. (6) showed that when
antibody was given to mice soon after infection, access to
the nervous system was reduced. More recent studies in a
variety of experimental models confirm this (1, 10-12, 14,
16-18, 26). However, this has not been shown to be the case
in all systems (4, 27). In any case, the presence of a high
level of antibodies does not apply to primary infection. Virus
reaches the ganglia early (24 to 48 h postinfection [4, 11, 14,
16]), long before a detectable antibody response has oc-
curred.
Most workers agree that T-cells are required for the
clearance of virus from established sites of infection (re-
viewed by Nash and Wildly [15]), although there remains a
possibility that antibody-mediated killing of infected cells
plays a supportive role (1, 2, 21, 22). We have, so far, failed
to show in vivo that any of the antibodies described in this
report can increase the already effective T-cell-mediated
clearance of virus from the skin (unpublished data). Anti-
body alone is not sufficient to cause virus clearance in the
absence of T-cell mechanisms either in vitro (16) or in vivo
(11), although clinical disease can be delayed (11).
In recurrent disease, virus reactivates in the presence of
antibody, both naturally in humans (3, 5, 24) and in experi-
mental models (8, 20). It therefore appears that normally
acquired levels of antibodies are insufficient to prevent
recurrent ganglionic infection and, in many instances, re-
crudescent skin lesions. Our results agree that antibodies are
of limited value in clearing virus from the skin in primary and
recurrent infection; however, our results suggest that a
heightened immune response may be able to interrupt the
process of epidermal infection which must occur before a
recrudescent lesion can appear. Therapy for various clinical
presentations of herpetic infection is anxiously sought. The
possibility that high-titer monoclonal antibodies might be
useful in prophylaxis against the lethal herpetic infections
seen in the immunocompromised host is intriguing and
deserves further investigation. In addition, the more com-
mon recurrent epidermal infections lead to misery and
discomfort for many millions worldwide. The recent sugges-
tion that vaccines may both protect against primary disease
and reduce the frequency and severity of recrudescent
lesions (G. Skinner, personal communication) has aroused
considerable interest. It is possible that such protection
could result from an elevated (qualitative rather than quan-
titative) antibody response, leading to protection mediated
by the mechanism described here. Certainly, it is apparent
that there is a need for further investigation into the immuno-
therapy of herpes simplex virus infections.
ACKNOWLEDGMENTS
This work was supported by a grant from the Medical Research
Council of Great Britain.
We thank P. Wildy for invaluable assistance during the prepara-
tion of this manuscript.
LITERATURE CITED
1. Balachandran, N., S. Bacchetti, and W. E. Rawls. 1982. Protec-
tion against lethal challenge of BALB/c mice by passive transfer
of monoclonal antibodies to five glycoproteins of herpes simplex
virus type 2. Infect. Immun. 37:1132-1137.
2. Baron, S., M. G. Worthington, J. Williams, and J. W. Gaines.
1975. Post exposure serum prophylaxis of neonatal herpes
simplex virus infection of mice. Nature (London) 261:505-506.
3. Centefanto, Y. M., J. M. Little, and H. E. Kaufman. 1970. The
relationship between virus chemotherapy, secretory antibody
formation and recurrent herpetic disease. Ann. N.Y. Acad. Sci.
173:649-655.
4. Cook, M. L., and J. G. Stevens. 1973. Pathogenesis of herpetic
neuritis and ganglionitis in mice: evidence for intra-axonal
transport of infection. Infect. Immun. 7:272-288.
5. Douglas, R. G., and R. B. Couch. 1970. A prospective study of
chronic herpes simplex virus infection and recurrent herpes
labialis in humans. J. Immunol. 104:289-295.
6. Evans, C. A., H. B. Slavin, and G. P. Berry. 1946. Studies on
herpetic infection in mice. IV. The effect of specific antibodies
on the progression of the virus within the nervous system of
young mice. J. Exp. Med. 84:429-477.
7. Field, H. J., S. E. Bell, G. B. Elion, A. A. Nash, and P. Wildy.
1979. Effect of acycloguanosine treatment on acute and latent
herpes simplex infections in mice. Antimicrob. Agents Chemo-
ther. 15:554-561.
8. Hill, T. J., H. J. Field, and W. A. Blyth. 1975. Acute and
recurrent infection with herpes simplex infection in the mouse:
a model for studying latency and recurrent disease. J. Gen.
Virol. 28:341-353.
9. Hooks, J. J., W. Burns, K. Hayashi, S. Geis, and A. L. Notkins.
1976. Viral spread in the presence of neutralizing antibody:
mechanisms of persistence in foamy virus infection. Infect.
Immun. 14:1172-1178.
10. Kapoor, A. K., A. A. Nash, P. Wildy, J. Phelan, C. S. McLean,
and H. J. Field. 1982. Pathogenesis of herpes simplex virus in
congenitally athymic mice: the relative roles of cell mediated
and humoral immunity. J. Gen. Virol. 60:225-233.
11. Kino, Y., Y. Hayashi, I. Hayashida, and R. Mori. 1982. Dissem-
ination of herpes simplex virus in nude mice after intracutane-
VOL. 53, 1985
948 SIMMONS AND NASH
ous inoculation and the effect of antibody on the course of
infection. J. Gen. Virol. 63:475-479.
12. Luyet, F., D. Samra, A. Soneji, and M. I. Marks. 1975. Passive
immunization in experimental Herpesvirus hominis infection of
newborn mice. Infect. Immun. 12:1258-1261.
13. McKendall, R. R. 1983. Delayed IgG mediated clearance of
herpes simplex type 1 from the CNS but not footpad during the
early stages of infection: possible result of relative integrity of
the blood-brain barrier. J. Gen. Virol. 64:1965-1972.
14. McKendall, R. R., T. Klassen, and J. R. Baringer. 1979. Host
defenses in herpes simplex infections of the nervous system:
effect of antibody on disease and viral spread. Infect. Immun.
23:305-311.
15. Nash, A. A., and P. Wildy. 1983. Immunity in relation to the
pathogenesis of herpes simplex virus, p. 179-192. In F. A.
Ennis (ed.), Human immunity to viruses. Academic Press, Inc.,
New York.
16. Openshaw, H., L. V. S. Asher, C. Wohlenberg, T. Sekizawa, and
A. L. Notkins. 1979. Acute and latent infection of sensory
ganglia with herpes simplex virus: immune control and virus
reactivation. J. Gen. Virol. 44:205-215.
17. Paven, P. R., and F. A. Ennis. 1977. The elimination of herpes
simplex plaques by antibody and the emergence of resistant
strains. J. Immunol. 118:938-940.
18. Price, R. W., M. A. Walz, C. Wohlenberg, and A. L. Notkins.
1975. Latent infection of sensory ganglia with herpes simplex
virus: efficacy of immunisation. Science 188:938-940.
19. Russell, W. C. 1962. A sensitive and precise assay for herpes
virus. Nature (London) 195:1028-1029.
20. Sekizawa, T., and H. Openshaw. 1984. Encephalitis resulting
from reactivation of latent herpes simplex virus in mice. J.
Virol. 50:263-266.
21. Shimizu, F., K. Hanaumi, Y. Shimizu, and K. Kumagai. 1977.
Antibody dependent cellular protection against herpes simplex
virus dissemination as revealed by viral plaque and infectivity
assays. J. Immunol. 116:531-536.
22. Shore, S. L., A. J. Nahmias, S. E. Starr, P. A. Wood, and D. E.
Macfarlin. 1974. Detection of cell dependent cytotoxic antibody
to cells infected with herpes simplex virus. Nature (London)
251:350-352.
23. Simmons, A., and A. A. Nash. 1984. Zosteriform spread of
herpes simplex virus as a model of recrudescence and its use to
investigate the role of immune cells in prevention of recurrent
disease. J. Virol. 52:816-821.
24. Spruance, S. L., J. C. Overall, Jr., E. R. Kern, G. G. Kreuger,
V. Pliam, and W. Miller. 1977. The natural history of recurrent
herpes simplex labialis: implications for antiviral therapy. N.
Engl. J. Med. 297:69-75.
25. Teague, O., and E. W. Goodpasture. 1923. Experimental herpes
zoster. J. Med. Res. 24:185-200.
26. Tullo, A. B., C. Shimeld, W. A. Blyth, T. J. Hill, and D. L.
Easty. 1982. Spread of virus and distribution of latent infection
following ocular herpes simplex in the non-immune and immune
mouse. J. Gen. Virol. 63:95-101.
27. Wildy, P. 1967. The progression of herpes simplex virus to the
central nervous system of the mouse. J. Hyg. 65:173-192.
J. VIROL.
